AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$12.29

Market cap

$1.58B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.12

Enterprise value

$1.43B

Sector: Healthcare
Industry: Biotechnology
Website: https://www.auriniapharma.com

Highlights

AUPH's equity is up by 41% year-on-year but it is down by 9% since the previous quarter
The quick ratio rose by 33% since the previous quarter but it has declined by 19% year-on-year
Aurinia Pharmaceuticals's debt has surged by 52% YoY and by 6% QoQ
The net income has decreased by 34% YoY and by 33% from the previous quarter

Key stats

What are the main financial stats of AUPH
Market
Shares outstanding
128.16M
Market cap
$1.58B
Enterprise value
$1.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.23
Price to sales (P/S)
30.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.99
Earnings
Revenue
$51M
EBIT
-$136.4M
EBITDA
-$134.74M
Free cash flow
-$109.1M
Per share
EPS
-$1.12
Free cash flow per share
-$0.86
Book value per share
$2.9
Revenue per share
$0.4
TBVPS
$3.2
Balance sheet
Total assets
$417.08M
Total liabilities
$46.85M
Debt
$8.88M
Equity
$370.23M
Working capital
$351.1M
Liquidity
Debt to equity
0.02
Current ratio
17.6
Quick ratio
16.52
Net debt/EBITDA
1.1
Margins
EBITDA margin
-264.2%
Gross margin
99.9%
Net margin
-267.7%
Operating margin
-249.7%
Efficiency
Return on assets
-33.3%
Return on equity
-38.6%
Return on invested capital
-87.4%
Return on capital employed
-34.5%
Return on sales
-267.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
3.1%
1 week
22.9%
1 month
-0.49%
1 year
-28.38%
YTD
-11.14%
QTD
-5.39%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$51M
Gross profit
$50.95M
Operating income
-$127.35M
Net income
-$136.53M
Gross margin
99.9%
Net margin
-267.7%
Aurinia Pharmaceuticals's net margin has surged by 99% YoY but it has decreased by 31% QoQ
The operating margin has soared by 99% YoY but it has decreased by 20% from the previous quarter
The net income has decreased by 34% YoY and by 33% from the previous quarter
The operating income is down by 24% year-on-year and by 22% since the previous quarter

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.23
P/S
30.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.99
Aurinia Pharmaceuticals's EPS has decreased by 29% QoQ and by 8% YoY
AUPH's equity is up by 41% year-on-year but it is down by 9% since the previous quarter
The price to book (P/B) is 17% lower than the last 4 quarters average of 5.1
The stock's P/S is 99% less than its last 4 quarters average of 5000.6 and 99% less than its 5-year quarterly average of 2500.6

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
Aurinia Pharmaceuticals's return on sales has surged by 99% YoY but it has decreased by 30% QoQ
AUPH's ROIC has soared by 97% year-on-year and by 13% since the previous quarter
The company's return on assets fell by 25% QoQ but it rose by 23% YoY
The ROE has increased by 23% YoY but it has decreased by 23% from the previous quarter

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's current ratio has increased by 34% from the previous quarter but it has decreased by 16% YoY
The quick ratio rose by 33% since the previous quarter but it has declined by 19% year-on-year
Aurinia Pharmaceuticals's debt is 98% lower than its equity
Aurinia Pharmaceuticals's debt has surged by 52% YoY and by 6% QoQ
AUPH's equity is up by 41% year-on-year but it is down by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.